Why REGENERON PHARMACEUTICALS (NASDAQ:REGN) Deserves Consideration as a Quality Investment.

Quality investors are looking for the best of the best. Companies which are growing steadily and consistently, but are also in excellent financial condition. We will have a look here to see if REGENERON PHARMACEUTICALS (NASDAQ:REGN) is suited for quality investing. Investors should of course do their own research, but we spotted REGENERON PHARMACEUTICALS showing up in our Caviar Cruise quality screen, so it may be worth spending some more time on it.

Why REGN may be interesting for quality investors.

• REGN has achieved substantial revenue growth over the past 5 years, with a 12.55% increase. This signifies the company's ability to successfully capture market opportunities and generate sustained revenue growth.
• The ROIC excluding cash and goodwill of REGN stands at 40.49%, reflecting the company's strong financial management and profitability. This metric underscores its ability to generate favorable returns on the capital invested in its core operations.
• With a Debt/Free Cash Flow Ratio of 0.76, REGN exhibits solid financial health and responsible debt management practices. This ratio indicates the company's ability to generate ample free cash flow to meet its debt obligations and pursue growth opportunities.
• With a robust Profit Quality (5-year) ratio of 77.84%, REGN highlights its ability to consistently generate high-quality profits. This metric reflects the company's effective management and operational excellence in delivering reliable earnings over the long term.
• REGN has consistently achieved strong EBIT growth over the past 5 years, with a 13.8% increase. This underscores the company's effective management of its operating income and suggests a positive outlook for future profitability.
• REGN has achieved impressive EBIT 5-year growth, surpassing its Revenue 5-year growth. This indicates the company's ability to improve its profitability and operational efficiency, highlighting its strong financial performance.

Fundamental analysis of REGN

ChartMill assigns a Fundamental Rating to every stock. This score, ranging from 0 to 10, is updated daily and is determined by evaluating multiple fundamental indicators and properties.

REGN gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 566 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making REGN a very profitable company, without any liquidiy or solvency issues. REGN is valued quite cheap, while showing a decent growth score. This is a good combination! This makes REGN very considerable for value and quality investing!

For an up to date full fundamental analysis you can check the fundamental report of REGN

Our Caviar Cruise screen will find you more ideas suited for quality investing.

Disclaimer

This article should in no way be interpreted as advice. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.